ATP Induces Disruption of Tight Junction Proteins via IL-1 Beta-Dependent MMP-9 Activation of Human Blood-Brain Barrier In Vitro

Figure 1

A438079 attenuates BzATP-induced disruption of blood-brain barrier in vitro. (a) The IL-1β level was significantly higher in BzATP groups than in control groups (). A438079 treatment significantly reduced the levels of IL-1β compared with the vehicle group (). (b) The level of MMP-9 was significantly higher in BzATP groups than in control groups (). A438079 treatment significantly reduced the level of MMP-9 compared with the vehicle group (). (c) BzATP induced hyperpermeability compared with the control groups (), which was decreased by the P2X7 inhibitor A438079 in the coculture system (). (d) Western blot analysis showed that the expression of ZO-1 and occludin in the BzATP groups was decreased compared with the controls (), while A438079 treatment significantly attenuated the disruptions of ZO-1 and occludin ().

(a)

(b)

(c)

(d)